Related Experiment Videos
[Therapy of primary open-angle glaucoma by oftan-dipivefrin]
Vestnik Oftalmologii
|March 31, 2000
Summary
Oftan-dipivefrin demonstrated a more pronounced hypotensive effect in glaucoma patients, while Glaucon offered fewer side effects. Both treatments, combined with pilocarpine, effectively lowered intraocular pressure.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Glaucoma management requires effective hypotensive therapy with minimal adverse effects.
- Selecting optimal treatments for intraocular pressure reduction is a significant clinical challenge.
Purpose of the Study:
- To compare the efficacy and safety of oftan-dipivefrin and glaucon in glaucoma patients.
- To evaluate the hypotensive effects and side effect profiles of two distinct therapeutic agents.
Main Methods:
- A randomized, open-label, parallel study involving 60 patients aged 61-69 years.
- Patients received either oftan-dipivefrin or glaucon for 8 weeks, with a 7-day washout period prior.
- Intraocular pressure, visual acuity, tonography, and visual fields were monitored daily and periodically.
Main Results:
- Both oftan-dipivefrin and glaucon significantly reduced intraocular pressure when used with pilocarpine.
- Oftan-dipivefrin exhibited a more pronounced hypotensive effect compared to glaucon.
- Glaucon was associated with a lower incidence of side effects.
Conclusions:
- Both oftan-dipivefrin and glaucon are effective in managing glaucoma, with varying profiles of efficacy and tolerability.
- The choice of therapy may depend on balancing the degree of intraocular pressure reduction with the patient's tolerance for side effects.